While more biosimilars gained regulatory approval 2017 and neared their entry into the US marketplace, physician acceptance of these products proved to be a challenge.
While more biosimilars gained regulatory approval in 2017 and neared their entry into the US marketplace, physician acceptance of these products proved to be a challenge.
A survey of community-based US oncologists and hematologists found that:
The researchers in this study concluded that significant gaps in education pose a barrier to physicians’ acceptance of oncology biosimilars, and 2 posters presented at the American College of Rheumatology’s 2017 meeting in San Diego, California, pointed to similar gaps in US rheumatologists’ knowledge.
In the first, a survey of practicing rheumatologists, approximately 60% of respondents were unlikely to switch from a reference biologic to a biosimilar in patients who were responding well to their current therapy. Additionally, 21% of respondents were extremely likely or likely to switch to a biosimilar if the patient was failing to respond well to the originator.
In the second survey, in which respondents were rheumatologists or rheumatology practice managers, only 51% understood the concept of interchangeability, only 40% believed that biosimilars had equivalent safety and efficacy to their references, and 20% said they would not prescribe a biosimilar.
The results of such surveys led Stacie Phan, MBA, MS, president of the Biosimilars Forum, to write in a contributor article at The Center for Biosimilars® that “Researchers who worked on both surveys concluded that physicians’ lack of knowledge about biosimilars and their ambivalence about prescribing these drugs present a significant barrier for building a robust biosimilars market in the United States. This barrier has implications not only for patients suffering from RA, but also from psoriatic arthritis, Crohn disease, ulcerative colitis, and various types of cancer—including breast cancer, metastatic colorectal cancer, non-squamous non-small cell lung cancer, and glioblastoma.”
Phan called for physicians to educate themselves about these therapies for the good of their patients: “We need a medical community that is fully educated about the benefits of biosimilars so that the promise of these drugs can be fully realized in the United States,” she said.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.